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Globally, there is a huge lack of relevant research about widespread lifestyle diseases and 
living conditions in indigenous communities. Northern and Middle Norway have a history of 
multiple ethnic groups, and the Sami has been acknowledged as the indigenous people of 
Norway by the Norwegian State. The SAMINOR 2 Clinical Survey, a part of the SAMINOR 
Study, was carried out to provide health information about the Sami population in Norway.  
Methods 
The cross-sectional population-based SAMINOR 2 Clinical Survey consists of both 
questionnaires and a clinical examination performed in 10 municipalities during 2012-2014.   
Results 
In total, 6004  men and women (participation rate 48%) aged 40-79 years, attended.   
In inland Finnmark, the Sami are the majority (80-90%) as opposed to the coastline of Troms 
and Nordland, where the Sami population form a minority (20%). More women than men 
participated (54% versus 43%, respectively). Obesity was prevalent in this sample, and a high 
mean glycated hemoglobin was observed.  
Conclusions 
This article describes the methods and data collection of the SAMINOR 2 Clinical Survey and 
presents some characteristics of the sample. The definition of ethnic groups is a core question 
in the survey, and includes several criteria. To ensure that indigenous values and priorities are 
reflected in the research themes, we recommend that future research projects be directed in 
close collaboration with the Sami Parliament and the local communities.   
 




 The SAMINOR Clinical Survey provide important insight regarding lifestyle and 
disease development in the indigenous Sami population, as well as the general 
population in these rural municipalities of Northern Norway 
 The definition of ethnic groups is a core question in the survey. One main challenge is 
the lack of ethnic identifiers in national data systems due to legislative prohibitions 
against the collection of data on ethnicity. Therefore, in health research, indigenous 
identification relies on self-reporting 
 The education level was high, including in areas in which the Sami are in the majority 
 SAMINOR data are a shared resource, planned and formed together with the 














The Second Clinical Survey of the Population-based Study on Health and 
Living Conditions in Regions with Sami and Norwegian Populations - the 
SAMINOR 2 Clinical Survey. 
Performing Indigenous Health Research in a Multiethnic Landscape 
 
Background 
Worldwide, there is increasing focus on the health of indigenous peoples. Previous studies 
have reported poorer outcomes for key health indicators among indigenous populations than 
benchmark populations (1-4). Indigenous populations often represent a minority group in the 
countries in which they reside, and they suffer from a disproportionate burden of morbidity 
and mortality (1, 5). These health gaps may be attributed in part to differences in 
socioeconomic status and living conditions (1, 6). Still, there is an enormous lack of relevant 
research on lifestyle diseases and living conditions in indigenous communities.  
The Sami are acknowledged by the Norwegian State as an indigenous people (7). Sápmi – 
the traditional Sami settlement area – has been inhabited by the Sami for thousands of years. 
Sápmi covers the northern parts of Norway, Sweden, Finland, and Russia’s Kola Peninsula, 
with the largest proportion of the Sami population living in Norway (8). There are grave 
deficiencies in demographic information on the Sami population, with no existing reliable or 
updated records, but the estimates of the total number of Sami in Norway usually vary 
between 40,000 and 50,000.  
Sápmi is also home to the Kvens, who are the descendants of Finnish-speaking settlers 
who immigrated from Sweden and Finland to Northern Norway in the 1700s and 1800s (9). 
The Kvens were recognized as a national minority in 1998, although they are not indigenous.  
This paper presents a synopsis of the SAMINOR 2 Clinical Survey and aims to give an 
overview of the objectives, study design, data collection, attendance, some clinical findings 
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and characteristics of the participants; and highlight the study as an example of how to 
perform health research among indigenous populations. 
 
Settings  
Finnmark, Troms, and Nordland Counties are generally referred to as Northern Norway and 
consists of 87 municipalities with a population size in 2014 of 482,000 inhabitants (10). The 
following 10 municipalities were included in the SAMINOR 2 Clinical Survey: Kautokeino, 
Karasjok, Porsanger, Tana, Nesseby, Kåfjord, Storfjord, Lyngen, Skånland, and Evenes 
(Figure 1). These 10 municipalities were also included in the SAMINOR 1 Survey (2003-
2004) (11) and the SAMINOR 2 Questionnaire Survey (2012-2014) (12). Due to limited 
resources, only 10 of the 24 participating municipalities in the preceding SAMINOR 1 Survey 
were included in the present survey.  Areas where we expected to find a high proportion of 
people with a Sami background were selected (11). Altogether, the SAMINOR 1 Survey, the 
SAMINOR 2 Questionnaire Survey, and the SAMINOR 2 Clinical Survey constitute the 
SAMINOR Study. 
In the present paper, we categorized the 10 municipalities in the SAMINOR 2 Clinical 
Study into four regions (Figure 1), according to their dialect, culture, geographic location, and 
proportion of inhabitants of Sami ethnicity. Region 1 includes the inland municipalities of 
Kautokeino and Karasjok in Finnmark County, where the Sami represent a large majority. 
Region 2 consists of the other municipalities in Finnmark County, namely Tana, Nesseby, and 
Porsanger, which have vast inland tundra areas in addition to coastline. Region 3 consists of 
three municipalities in the coastline of the northern part of Troms County: Kåfjord, Storfjord, 
and Lyngen. Finally, Region 4 consists of Skånland and Evenes municipalities, located on the 





All citizens aged 40-79 years in the selected municipalities were invited (n=12,577). After the 
removal of duplicates, and the exclusion of those who had moved, died, or had incorrect 
addresses, the final eligible study sample was 12,455. Of these, 6,004 (48.2%) men and 
women participated (Figure S1 in the supplementary material).   
 
Logistics 
A small team of 3-5 employees (researchers, technicians, and administrative personnel) from 
the Centre for Sami Health Research (CSHR) at UiT The Arctic University of Norway 
conducted, planned, and implemented the SAMINOR 2 Clinical Survey, along with 
temporarily-employed fieldworkers who were primarily local, certified health workers.  
All the necessary equipment, such as individual sampling kits, instruments, computers, 
refrigerators, and freezers were prepared and packed at the UiT The Arctic University of 
Norway and transported by removal companies. The CSHR team had preparatory meetings 
with municipal authorities and health professionals to inform them about the survey and 
ensure they would promote the survey through municipal websites and other media.  
 
Invitation  
One to 2 months prior to the data collection, data on the name, postal address, and unique 
national personal identification number of the target population to be invited were collected 
from the Norwegian National Population Register at the Norwegian Tax Administration, and 
each invitee was assigned a unique identity code (survey ID). Three to 4 weeks before the 
survey began, a pamphlet was posted to inform invitees about the coming survey. 
Approximately 2 weeks prior to data collection, the invitation letter was posted to invitees; it 
included an appointment time, an informational brochure and a questionnaire, which 
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contained invitee’s assigned study ID. Halfway through the data collection period, a reminder 
was sent to invitees who had not yet attended.  
The pamphlet, informational brochure, invitation letter and questionnaire were developed 
in Norwegian, but also translated into Northern Sami by professional translators (Table S1 in 
the supplementary material).  
The pamphlet and the informational brochure were also translated into Kven. All 




Data was collected through self-administered questionnaires, clinical examinations and blood 
sampling. Depending on the population size, data collection in each municipality was 
conducted within 2-7 weeks.  
 
Questionnaires 
An eight-page, self-administered questionnaire was posted to invitees aged 40-69 years, 
whereas those aged 70-79 years received a four-page questionnaire with fewer questions and 
larger fonts. The questionnaires were developed in collaboration with various researchers and 
included a combination of new questions and questions from previous SAMINOR surveys or 
other comparable surveys. The questionnaires covered information regarding selected 
diseases, as well as health-related topics, chronic pain (World Health Organization pain scale) 
(13, 14), socio-economic status, ethnicity, physical activity, tobacco and drug/alcohol use, and 
oral/dental health. For women, questions on childbirth and breastfeeding were included. In 
addition, the questionnaire for invitees aged 40-69 years included a food frequency 
questionnaire adapted from the Norwegian Women and Cancer (NOWAC) Study (15), 
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together with questions regarding sun-bathing habits, use of skin care products, body size 
perception, anxiety/depression (“The Hopkins Symptom Checklist, HSCL-5”) (16), and 
sleeping patterns. Experiences with health care services including the use of a Sami-speaking 
interpreter, was included in the questionnaire addressed to invitees aged 70-79 years.  
The questions regarding ethnicity were identical to those used in former SAMINOR 
surveys. A total of 11 questions covered language, ethnic background, and self-perceived 
ethnicity: "What language(s) do/did you, your parents and your grandparents use at home?"; 
The questions about home language are objective criteria used in the definition of ethnicity.  
"What is your, your father’s and your mother’s ethnic background?"; Ethnic background is a 
form of cultural identity that is created and maintained through contacts with other groups and 
also reflects what the surrounding define the participant to be. The last question “What do you 
consider yourself to be?” reflects the participant’s own self-perceived ethnicity/identity and is 
a subjective criterion. On all questions the response options were: “Norwegian”, “Sami”, 
“Kven”, and “Other”. The questions were to be answered separately for each relative and 
multiple choices were allowed. Sami ethnicity can be defined in different ways, depending on 
the criteria. In the present paper, Sami affiliation is defined when the participant responded 
“Sami” to at least one of these questions. This is the widest possible definition. 
 
Clinical examination, blood sampling, and biobanking 
The procedures followed a strict protocol, in which all fieldworkers became proficient during 
their training.  
Once called for examination, participants were registered, signed a written consent form, 
and completed and handed in their questionnaire. Then, height, weight, and body mass index 
(BMI, kg/m2) were measured using an electronic Height, Weight & Fatness Measuring 
System device (DS-103, Dongsahn Jenix, Seoul, Korea) with the participants wearing light 
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clothes and no shoes. Body weight was measured in kilograms with one decimal, and height 
was measured in cm with one decimal. Hip and waist circumference were measured with a 
band to the nearest centimeter with the participant standing erect. Waist circumference was 
measured at the umbilicus and hip circumference was measured at level of the iliac crest (hip 
bone), both to the nearest cm.   
Blood pressure and resting heart rate were measured, with the participant sitting with the 
arm resting at the level of the heart. The time interval between arrival to the examination site 
and blood pressure measurement was at least 15 minutes. Initially, the circumference of the 
upper part of the right (optimal) arm was measured to find the correct cuff. After a 2-minute 
rest, three measurements were taken at 1-minute intervals, using an automatic device 
(CARESCAPETMV100 monitor, GE Healthcare, Milwaukee, Wisconsin, USA). The mean of 
second and third measurements was used in the analysis.  
Finally, blood sampling was performed, following a strict quality protocol. Non-fasting 
blood samples were drawn by venipuncture with participants in a seated position. 
Descriptions of the blood analyses are provided in Supplementary material. Blood samples 
were stored on site at -20°C in a manual freezer and after some weeks transported to the 
biobank at UiT The Arctic University of Norway. The serum samples were later stored at -
70°C in manual ultra-freezers, while serum clots and serum and whole blood for persistent 
toxic substances and essential elements were stored at -35°C ((Table S2 in the supplementary 
material).  
A range of blood analyses have already been performed on these samples, including 
indicators for cardiovascular disease, diabetes mellitus, inflammation, hematology, vitamins, 




 In addition, blood samples for later analyses of novel biomarkers and DNA have been 
stored. 
 
Feedback to participants and medical recommendations 
Immediately after the examination, participants received information on their available 
clinical measures (height, weight, blood pressure, heart rate, hemoglobin (Hb), and glycated 
hemoglobin (HbA1c)) both orally and in writing in the Norwegian or Sami language. If there 
was an indication of pathology, participants were recommended to contact their general 
practitioner for a check-up. Medical referral included high blood pressure, tachycardia, 
elevated Hb, anemia, and elevated HbA1c. Recommendations were given according to the 
degree of severity, following pre-set cut-off values (Table 1). In case of serious pathology, the 
local general practitioner or hospital was contacted right away. 
 
Ethics 
The Norwegian Data Protection Authority and the Regional Committees for Medical and 
Health Research Ethics (REC North) approved the SAMINOR Study. The REC North also 
approved the present study. All participants gave written informed consent, which included a 
consent to later linkages to national registers, previous censuses, and cardiovascular 
screenings. Following the Norwegian Health Research Act (17), all research projects that plan 
to use data from the SAMINOR 2 Clinical Survey need approval from the REC North and 
from the SAMINOR Project Board.   
 
Privacy and data security 
Data is stored de-identified with a unique survey ID. The linkage between the survey ID and 
the person’s 11-digit national ID number is stored separately from the data file within the 
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secure EUTRO system, which is a module-based unique database solution for research, 
developed at the Department of Community Medicine, UiT The Arctic University of Norway.  
 
Statistics 
The participation rate is presented in numbers (n) and percent (%), stratified by sex and 5-year 
age groups. Sample characteristics and subjective and objective criteria of ethnicity were 
stratified by geographic region. Continuous variables are presented as means and standard 
deviations, and categorical variables are presented as number and percent. Geographic 
differences were tested by analysis of variance and by Pearson’s χ2 test, for continuous and 
categorical variables, respectively. Clinical measures and results of blood samples are 
presented as means and 95% confidence intervals (CI), stratified by sex and four age groups. 
Geometric mean was used in case of skewed distribution. All tests were two-sided with a 0.05 
significance level. SAS version 9.4 (SAS Institute, Cary, NC, USA) was used for data 
management and statistical analyses.  
 
Results 
Overall, more women than men participated (54.4% versus 42.5%, respectively) (Table 2). 
Participation increased with increasing age in both sexes, except for a lower participation for 
those aged 75-79 years. Participation was highest in Kautokeino municipality (56%) and 
lowest in Evenes municipality (41%). Participation was particularly high among women in 
Kautokeino (67%) (Figure 2).  
The highest mean age was among participants in Region 3 (60.2 years) and the lowest 
mean age was observed in Region 1 (58.3 years) (Table 3). The age group 60-69 years 
constituted one-third of the study sample. There were significant differences regarding marital 
status between regions, with the highest proportion of married couples in Region 4 and lowest 
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in Region 2. Cohabitation was most common in Region 2 and most infrequent in Region 3. 
The education level was high in this population, as 40% had 13 years or more of schooling. 
Region 3 stood out with a significantly lower education level than the other regions. 
In total, 54% of the study sample reported Sami affiliation. In Region 1, almost 90% of 
the participants had Sami affiliation. In contrast, Regions 3 and 4 had 39% and 20% Sami 
affiliation, respectively. In Region 1, a vast majority of the sample reported “Sami” as their 
domestic language, ethnic background, and self-perceived ethnicity, and reported to have four 
grandparents who spoke Sami at home (Table 4).  
The mean BMI among men was 28.3 kg/m2. The highest mean BMI was found in the 
youngest age group. The mean BMI among women was also high (28.0 kg/m2), and it was 
highest in the age group 60-69 years (27.9 kg/m2). Central obesity was also pronounced both 
for men and women, with mean waist circumferences of 99.6 cm and 93.2 cm, respectively 
















This paper presents the background, objective, and implementation of the SAMINOR 2 
Clinical Survey, which comprises a multi-ethnic population aged 40-79 years from 10 
municipalities of Northern Norway during 2012-2014. The scientific program of the survey 
includes several large public health issues, including cardiovascular diseases, diabetes 
mellitus, mental health, and health services, which are also national health priorities.  
The SAMINOR 2 Clinical Survey achieved a response rate of 48%, which is acceptable 
due to the short period of data collection in each municipality. The participation rate was 
lower than that in the SAMINOR 1 Survey (61%), conducted 10 years earlier. Declining 
response rates have also been observed in other population-based studies (18, 19). This 
decline can partly be explained by a change in design. In the SAMINOR 1 Survey, those in 
Finnmark and Troms counties who had not attended the clinical examination received a 
second invitation a couple of months later (11). Due to limited resources, a second chance to 
participate was not possible in the SAMINOR 2 Clinical Survey. Access to register-based 
data for non-responders is limited, due to strict regulations. However, information on sex, age, 
and municipality was available for all invitees, and non-responders were dominated by the 
youngest invitees and by men. The legislative prohibitions against the collection of data on 
ethnicity in national registers hinders our ability to assess whether the ethnic distribution in 
the survey reflects that of the actual population in the selected geographic area. Low 
participation and the fact that the survey only covered 10 municipalities raise questions about 
external validity. Indeed, all epidemiological studies raise concerns about generalizability 
from a specific study sample to the entire target population (20). Accordingly, it is unknown 
to what extent  the results from the SAMINOR 2 Clinical Survey illustrate the real health 
status and disease burden of the total Sami population or other inhabitants in Northern 
Norway. However, the internal validity can be high. In upcoming publications, potential 
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selection bias, internal validity, and generalizability issues and sensitivity analyzes, must be 
carefully discussed, in relation to each specific study focus.  
The history and development of the Sami people is considerably different from that of the 
benchmark population in Norway. Like other indigenous peoples, the Sami have been 
exposed to the pressure of colonization and assimilation for more than 100 years (21, 22). The 
assimilation process included prohibitions against using the Sami language in schools and 
other public places, promotion of Norwegian settlements in coastal Sami areas so the coastal 
Sami became a minority in their traditional settlement areas, in addition to several other 
initiatives to promote assimilation(23). This was later termed “Norwegianization”. (24, 25). 
According to the late Johan Albert Kalstad, this process can be described figuratively as a 
tsunami, where the devastating effect was most striking at the coast and declined toward the 
inland areas (personal communication). This historical backcloth is a challenge when 
collecting data. It is still controversial to focus on issues facing the Sami population in several 
of the municipalities included in the survey, and it is not known whether the historical trauma 
of Norwegianization influenced study participation. A focus on Sami language and ethnicity 
and the fact that the survey was performed by a Sami research center may have contributed to 
low participation in some regions. Non-Sami invitees may have perceived the survey as 
intended for people of Sami origin only, while Sami invitees may have found the questions 
too personal and invasive. On the other hand, Sami invitees may have felt reassured by the 
fact that the researchers were of their own people, as suggested by the high response rate in 
Sami majority areas (Kautokeino, Tana, and Nesseby). Overall participation was low in the 
coastal regions (Regions 3 and 4), where the assimilation process heavily influenced Sami 
self-identification and made any focus on Sami ethnicity controversial (21).  
The education level in our sample was high, including in areas in which the Sami are in the 
majority. This is in line with previous findings from the SAMINOR 1 Survey (11). 
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Educational opportunities increased in the decades following World War II, with the 
establishment of a university in Tromsø in 1968, in addition to several district colleges, which 
gave youth from Northern Norway the opportunity to pursue higher education in their own 
region. A Sami activist wave in the 1960s and 1970s caused young Sami adults, especially 
women, to pursue higher education (26, 27). Furthermore, the establishment of the Sami 
Parliament and other Sami institutions during the past 25–30 years increased the job 
opportunities for educated Sami in their home municipalities.  
 
Due to the heterogeneity of the population being studied, use of ethnicity as an 
independent variable in epidemiological research is challenging (28). The definition of ethnic 
groups is a core question in the SAMINOR Study, ascertained by 11 different questions. 
However, operationalization of the target population must be handled with care. As the 
questions include both objective and subjective criteria: Sami language, ethnicity, and 
identity, it is possible to categorize the participants into indigenous versus non-indigenous 
groups in several different ways. In this paper, we have shown some examples. It is 
recommended that each research project create ethnic categories based on what is most 
suitable for their specific topic. However, despite the complexities of identifying the Sami 
population, it is essential to collect indigenous health data for use in the development of better 
health services. 
In the present paper, we present only an overview of some central clinical measures. Mean 
BMI and waist circumference were rather high in all age groups and both sexes. High 
prevalence of obesity and metabolic syndrome was already verified in this population in the 
SAMINOR 1 Survey (11, 29). Obesity is recognized as a risk factor for metabolic syndrome 
and chronic lifestyle diseases like type 2 diabetes mellitus. Additional attention is consistently 
given to chronic diseases and unfavorable health factors, but also to factors that contribute to 
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overall health in areas with both Sami and non-Sami population. This knowledge is important 
to the health care system, health politicians, health researchers, and the public in general (30, 
31).  
The design of the SAMINOR 2 Clinical Survey makes it possible to identify the 
indigenous population as well as other ethnic groups, enabling ethnicity-specific analyses. By 
collecting information on self-reported ethnicity, the survey provides a unique opportunity to 
link a person’s ethnicity to information in national health registers, facilitated by the national 
11-digit unique personal identification number. In addition, the survey can be linked with 
other health surveys, including the SAMINOR 1 Survey and the SAMINOR 2 Questionnaire 
Survey.  
SAMINOR data are a shared resource, planned and formed together with the 
municipalities and the Sami Parliament in Norway. Good communication with each 
municipality and the Sami Parliament - before, during, and after data collection - was and is 
highly prioritized. Indeed, one main aim of the CSHR is to give research information back to 
the communities where the research is performed. Therefore, anonymous results on group 
level from the SAMINOR 2 Clinical Survey are communicated to each of the municipalities 
through health reports and population meetings. We emphasize that understanding and respect 
of Sami and non-Sami diversity, and people’s needs and aspirations, are essential in all 
research. It is of particular importance that the researcher obtain insight into the wide variety 
of life in the communities where research is done.  
This article presents only an overview of some of the data collected in the SAMINOR 2 
Clinical Survey. Upcoming publications from the survey will address lifestyle diseases and 
indicators, and nutritional topics. We recommend that future research projects be done in 
close collaboration with the Sami Parliament and local communities to ensure that indigenous 





The SAMINOR Clinical Survey has the potential to provide important insight regarding 
lifestyle and disease development in the indigenous Sami population, as well as the general 
population in these rural municipalities of Northern Norway. Self-reported ethnicity 
information enables comparisons between Sami and non-Sami participants. In the future, this 
data will be used in a wide range of studies, with a special focus on the health of the Sami 
population. All use of the data must be done with respect for the Sami people and with an 
understanding of the ethnic heterogeneity of the studied population.  
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Table 1. Cut-offs for medical referral with related recommendations. The SAMINOR 2 Clinical Survey 
(2012-2014). 
 





Table 2. Participation by sex and age group. The SAMINOR 2 Clinical Survey (2012-2014, n=12,455)*.  
 
 Men  Women  Total 
Age (years) Invited Attended (%)  Invited Attended (%)  Invited Attended (%) 
40–44 867 255 (29.4)  836 388 (46.4)  1,703 643 (37.8) 
45–49 907 283 (31.2)  795 364 (45.8)  1,702 647 (38.0) 
50–54 883 319 (36.1)  777 406 (52.3)  1,660 725 (43.7) 
55–59 897 372 (41.5)  848 481 (56.7)  1,745 853 (48.9) 
60–64 970 481 (49.6)  872 535 (61.4)  1,842 1,016 (55.2) 
65–69 930 488 (52.5)  817 504 (61.7)  1,747 992 (56.8) 
70–74 591 336 (56.9)  550 333 (60.5)  1,141 669 (58.6) 
75–79 424 213 (50.2)  491 246 (50.1)  915 459 (50.2) 
Total 6,469 2,747 (42.5)  5,986 3,257 (54.4)  12,455 6,004 (48.2) 
* The total population aged 40-79 years in 10 municipalities were invited. 
 
 
 Cut-off for medical referral Action/recommendation 
Systolic BP ≥155 mmHg Consult your GP within 1-2 months 
 ≥180 mmHg Consult your GP within a week 
   
Diastolic BP ≥90 mmHg Consult your GP within 1-2 months 
 ≥110 mmHg Consult your GP within a week 
 ≥120 mmHg Emergency action  
   
Pulse ≥100 BPM Consult your GP within 1-2 months 
 ≥120 BPM Consult your GP within 1-2 weeks 
 Irregular Consult your GP within 1 month 
   
Hb Women: >17.5 g/dl, men: >18.5 g/dl Consult your GP within 2 months 
 Women: <9 g/dl, men: <10 g/dl Consult your GP within 1-2 weeks 
 ≤8 g/dl Emergency action  
   
HbA1c ≥6.2% Consult your GP within 3 months 
 ≥12.0% Consult your GP within 1 months 
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Table 3. Sample characteristics by geographic regions. The SAMINOR 2 Clinical Survey (2012-2014, 
n=6,004). 















Skånland Total  
  (n=1,289) (n=2,011) (n=1,665) (n=1,039) (n=6,004) P-value 
Age (years), mean 
(SD) 
58.3 (10.4) 59.2 (10.4) 60.2 (10.6) 60.1 (10.2) 59.4 (10.5) <0.0001 
       
Age groups, n (%)      <0.0001 
 40–49 years 310 (24.0) 442 (22.0) 351 (21.1) 187 (18.0) 1,290 (21.5)  
 50–59 years 374 (29.0) 540 (26.9) 388 (23.3) 276 (26.6) 1,578 (26.3)  
 60–69 years 401 (31.1) 664 (33.0) 569 (34.2) 374 (36.0) 2,008 (33.4)  
 70–79 years 204 (15.8) 365 (18.2) 357 (21.4) 202 (19.4) 1,128 (18.8)  
 Total 1,289 2,011 1,665 1,039 6,004  
        
Sex, n (%)      0.06 
 Men 551 (42.7) 947 (47.1) 757 (45.5) 492 (47.4) 2,747 (45.8)  
 Women 738 (57.3) 1,064 (52.9) 908 (54.5) 547 (52.6) 3,257 (54.2)  
 Total 1,289 2,011 1,665 1,039 6,004  
        
Education (years), 
mean (SD) 
12.2 (4.6) 12.2 (3.8) 11.5 (3.8) 12.4 (3.7) 12.0 (4.0) <0.0001 
       
Education, n (%)      <0.0001 
 ≥13 years 528 (43.7) 822 (42.5) 546 (34.2) 425 (42.9) 2,321 (40.5)  
 <13 years 680 (56.3) 1,114 (57.5) 1,051 (65.8) 565 (57.1) 3,410 (59.5)  
 Total 1,208 1,936 1,597 990 5,731  
        
Marital status, n (%)      <0.0001 
 Married 698 (54.9) 1,009 (50.6) 1,026 (62.8) 668 (65.2) 3,401 (57.4)  
 Cohabiting 173 (13.6) 361 (18.1) 195 (11.9) 130 (12.7) 859 (14.5)  
 Divorced 110 (8.6) 243 (12.2) 121 (7.4) 79 (7.7) 553 (9.3)  
 Unmarried 208 (16.4) 267 (13.4) 164 (10.0) 83 (8.1) 722 (12.2)  
 Widow(er) 83 (6.5) 113 (5.7) 128 (7.8) 65 (6.3) 389 (6.6)  
 Total 1,272 1,993 1,634 1,025 5,924  











Table 4. Subjective and objective criteria of Sami heritage by geographic regions. The SAMINOR 2 
Clinical Survey (2012–2014, n=5,908). 
















  (n=1,269) (n=1,990) (n=1,624) (n=1,025) (n=5,908) 
  n (%) n (%) n (%) n (%) n (%) 
Domestic language (What language do you speak at home?) 
 Sami 909 (72.0) 418 (21.2) 21 (1.3) 19 (1.9) 1,367 (23.4) 
 Sami and Norwegian 129 (10.2) 198 (10.1) 66 (4.1) 37 (3.6) 430 (7.4) 
 Norwegian 199 (15.8) 1,234 (62.7) 1,472 (92.1) 937 (92.0) 3,842 (65.7) 
 Other 25 (2.0) 118 (6.0) 40 (2.5) 25 (2.5) 208 (3.6) 
 Total 1,262 1,968 1,599 1,018 5,847 
       
Ethnic background (Please indicate your ethnic background.) 
 Sami 1,022 (81.3) 584 (30.4) 71 (4.5) 118 (11.7) 1,795 (31.2) 
 Sami and Norwegian 74 (5.9) 297 (15.5) 193 (12.3) 50 (5.0) 614 (10.7) 
 Norwegian 129 (10.3) 870 (45.3) 1,232 (78.5) 812 (80.7) 3,043 (52.9) 
 Other 32 (2.5) 168 (8.8) 73 (4.7) 26 (2.6) 299 (5.2) 
 Total 1,257 1,919 1,569 1,006 5,751 
       
Self-perceived ethnicity (What (ethnicity) do you consider yourself to be?) 
 Sami 958 (76.1) 444 (22.5) 43 (2.7) 60 (5.9) 1,505 (25.7) 
 Sami and Norwegian 136 (10.8) 361 (18.3) 157 (9.7) 68 (6.7) 722 (12.3) 
 Norwegian 140 (11.1) 1,042 (52.9) 1,366 (84.6) 872 (85.5) 3,420 (58.3) 
 Other 25 (2.0) 122 (6.2) 48 (3.0) 20 (2.0) 215 (3.7) 
 Total 1,259 1,969 1,614 1,020 5,862 
       
Sami affiliation1 
 Sami 1,136 (89.5) 1,225 (61.6) 629 (38.7) 206 (20.1) 3,196 (54.1) 
 Non-Sami 133 (10.5) 765 (38.4) 995 (61.3) 819 (79.9) 2,712 (45.9) 
 Total 1,269 1,990 1,624 1,025 5,908 
       
Number of grandparents with Sami as their domestic language 
 4 955 (76.1) 608 (31.6) 252 (16.3) 114 (11.5) 1,929 (33.7) 
 1-3 147 (11.7) 502 (26.1) 299 (19.3) 52 (5.3) 1,000 (17.5) 
 0 153 (12.2) 815 (42.3) 997 (64.4) 824 (83.2) 2,789 (48.8) 
 Total 1,255 1,925 1,548 990 5,718 
1 Sami affiliation is used when the at least one of the following criteria were met: a) at least one 
parent, grandparent, or the respondents themselves spoke Sami as a domestic language, or b) the 
ethnic background of respondents or one of their parents was reported to be Sami, or c) the 








Table 5. Clinical measures reported to the participants, by sex and age group, means and 95% 
confidence intervals (CI). The SAMINOR 2 Clinical Survey (2012–2014, n=6,000). 
Age groups 40–49 years 50–59 years 60–69 years 70–79 years Total 










Men      
Smallest n–largest n1 536–538 686–691 966–969 546–549 2,737–2,746 


































































































































      
Women      
Smallest n–largest n1 747–752 879–887 1,037–1,039 577–579 3,245–3,254 




































































































































1 Numbers vary due to missing values. Smallest and largest n are therefore provided. 
2 Geometric mean due to skewed distribution. 
CI, confidence interval; BPM, beats per minute; HbA1c, glycated hemoglobin; Hb, hemoglobin; 
 
 





























SUPPLEMENTARY MATERIAL  
Biobanking and blood analyses  
This appendix shows an overview of the data collection and sampling (Table S1 and Figure S1). In 
addition, it describes the biobank and the analyses performed on blood samples (Tables S2 and S3). 
Glycated hemoglobin (HbA1c) and hemoglobin (Hb) were analyzed immediately on whole blood 
collected in a BD Vacutainer® K2 ethylene diamine tetraacetic acid (EDTA) 7.2 mg, 4 ml, REF# 368861). 
Remaining blood samples were sequentially processed into cryo-vials or pre-rinsed glass vials (serum 
PTS only): whole blood from one BD Vacutainer® (Trace element, K2 EDTA 10.8 mg, 4 ml, Ref# 
368381; BD, Franklin Lakes, USA); and, serum and clot, both extracted from centrifuged (38 X for 10 
minutes) 3 x BD Vacutainer® (SST™ II Advance, 10/8.5 ml, Ref# 367953). 
Almost all laboratory analyses were performed at the Laboratory of the Department of Clinical 
Chemistry, University Hospital of North Norway (UNN), Tromsø from September 2014 to November 
(Table 2). Vitamin D was analyzed at the Department of Food and Environmental Sciences, University 
of Helsinki, Finland. Contaminants and toxic and essential elements were analyzed on parts of the 
sample at the Norwegian Institute for Air Research (NILU), Tromsø, Norway, and National Institute of 
Occupational Health (STAMI), Oslo, Norway, respectively.  
 
Information about the different blood samples, dates of analysis and total numbers are included in 
Tables 1 and 2 of this appendix.  
 
Table S1. Overview of the data collection. The SAMINOR 2 Clinical Survey (2012-2014). 







Questionnaire Invitation letter 
Skånland/Evenes 2012 Sept. 17th 
– Oct. 25 th 
11 Norwegian Norwegian Norwegian 
Karasjok 2013 Jan. 28th – 
Febr. 21 th 
14 Norwegian/Sami Norwegian/Sami Norwegian/Sami 
Kautokeino 2013 Febr. 25th 
– Mar. 21th 
10 Norwegian/Sami Norwegian/Sami Norwegian/Sami 
Porsanger 2013 Apr. 15th – 
May. 30th 
9 Norwegian/Sami/Kven Norwegian 2 Norwegian/Sami 
Kåfjord 2013 Sept. 16th – 
Oct. 11th 
9 Norwegian/Sami Norwegian 2 Norwegian 
Storfjord 2013 Oct. 16th – 
Nov. 7th 
7 Norwegian/Sami/Kven Norwegian 2 Norwegian 
Nesseby 2014 Febr. 12th 
– Febr. 25th 
6 Norwegian/Sami Norwegian/Sami Norwegian/Sami 
Tana 2014 Febr. 27th 
– Apr. 3th 
11 Norwegian/Sami Norwegian/Sami Norwegian/Sami 
Lyngen 2014 May. 7th – 
June. 12th 
10 Norwegian/Sami Norwegian 2 Norwegian 
1 In some municipalities the health examination site was closed from 1 up to 4 weekdays due to 
public holidays  
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2 The Sami questionnaire was available on request 
 
 
Figure S1. Sample description of the SAMINOR 2 Clinical Survey (2012 – 2014) 
Original sample: 12,577 
Dead, moved or incorrect address: 118 

















Table S2. Collected blood samples. The SAMINOR 2 Clinical Survey (2012-2014). 
 n Type of tube Amount Stored at 
Total number of participants 6004    
Agreed to blood sampling 5998    
Blood sampling performed 5996    
Whole blood designated for Hb 5991 EDTA 4ml – 
Whole blood designated for HbA1c 5982 EDTA 4ml – 
Whole blood designated for metal analyses 5974 Cryo 2ml -20°C/-35°C 
Serum designated for lipid analyses 5976 Cryo <2ml -20°C/-70°C 
Serum designated for Vitamin D analyses 5954 Cryo 1ml -20°C/-70°C 
Serum designated for contaminant analyses 5953 Cryo 2ml -20°C/-70°C 
Whole blood for storage in biobank 5978 Cryo 2ml -20°C/-35°C 
Serum sample 1 for storage in biobank 5921 Cryo 2ml -20°C/-70°C 
Serum sample 2 for storage in biobank 5829 Cryo 2ml -20°C/-70°C 
Serum sample 3 for storage in biobank 4039 Cryo 2ml -20°C/-70°C 
Clot (DNA) for storage in biobank 5975 SST 10ml -20°C/-70°C 
 
Table S3. Overview of the analyzed blood samples. The SAMINOR 2 Clinical Survey (2012-2014). 
Table  n Date of analysis 
At least one blood analysis available 5996  
Hb 5991 17 Sep 2012-12 Jun 2014 
HbA1c 5982 17 Sep 2012-12 Jun 2014 
Serum analyzed UNN 5975 6 Sep 2014-9 Nov 2014 
 s-Ferritin 5975 6 Sep 2014-9 Nov 2014 
 s-Transferrin 5972 6 Sep 2014-9 Nov 2014 
 s-Iron 5974 6 Sep 2014-9 Nov 2014 
 Vitamin B12 5974 6 Sep 2014-9 Nov 2014 
 Folate 5866 6 Sep 2014-9 Nov 2014 
 HS-CRP 5972 6 Sep 2014-9 Nov 2014 
 Random plasma glucose 5974 6 Sep 2014-9 Nov 2014 
 Apolipoprotein-A 5974 6 Sep 2014-9 Nov 2014 
 Apolipoprotein-B 5973 6 Sep 2014-9 Nov 2014 
 Total cholesterol 5974 6 Sep 2014-9 Nov 2014 
 LDL cholesterol 5939 6 Sep 2014-9 Nov 2014 
 HDL cholesterol 5974 6 Sep 2014-9 Nov 2014 
 Triglycerides 5975 6 Sep 2014-9 Nov 2014 
 Transferrin saturation 5971 6 Sep 2014-9 Nov 2014 
25-hydroxy-vitamin D analyzed at Helsinki University 5953 2 Jun 2016 
Toxic and essential elements analyzed at STAMI 470 27 Apr 2016 
Contaminants analyzed at NILU 462 20 Apr 2017 
 
Description of blood analyses 




Hb was analyzed by the hemoglobincyanide (HiCN) method on a HemoCue Hb 201+ 1. A drop of 
blood was placed on a hydrophobic surface, e.g., plastic fil, using a pipette, and a microcuvette was 
filled. The internal and external quality controls showed values within established control limits. 
Internal quality control was conducted daily with heamolysate.  
 
Glycated haemoglobin  
HbA1c was analyzed with The DCA Vantage™ (Siemens Medical Solutions Diagnostics, Tarrytown, 
NY), which is based on latex agglutination inhibition immunoassay methodology and provides results 
in 6 minutes 2. This is the successor of the DCA 2000™. Internal and external quality controls showed 
values within established control limits. The internal quality control was conducted daily or when 
new reagents were opened. The inter-assay coefficient for variations (CV) for HbA1c was <3% 3.  
 
Serum ferritin 
Serum ferritin (s-ferritin) was measured on the Cobas 8000 system from Roche/Hitachi with an 
electrochemiluminescense immunoassay (ECLIA) 4 using the sandwich principle. Ferritin ( REF 
04491785) has been a standardized against the Ferritin assay (REF 11820982). The Ferritin assay (REF 
11820982) has been standardized against the Enzymun – Test Ferritin method. This in turn has been 
standardized against the 1st International Standard (IS) National Institute for Biological Standards 
and Control (NIBSC) “Reagent for Ferritin (human liver)” 80/602 5. The analyzer automatically 
calculates the analyte concentration of each sample in µg/l.  
 
Serum transferrin 
Transferrin was measured on the Cobas 8000 system from Roche/Hitachi with a by 
immunoturbidimetric assay using human transferrin, which forms a precipitate with a specific 
antiserum 6,7. This system automatically calculates the analyte concentration of each sample in 
mg/dlx 0,01=g/l. This method has been standardized against the reference preparation of the 
Institute for Reference Materials and Measurements (IRMM) BCR470/CRM470 (Reference 





Serum iron was measured on the Cobas 8000 system from Roche/Hitachi with a colorimetric method. 
This method has been standardized against a primary reference material (SRM 937) 5,9.  
 
Vitamin B12 
Vitamin B12 was measured on the Cobas 8000 system from Roche/Hitachi with by ECLIA 5,10,11 using 
the competitive principle. Results were determined via a calibration curve, which is an instrument 
specifically generated by 2-point calibration and a master curve provided by the reagent barcode. 
This method has been standardized against the Vitamin B12 assay (REF 11820753) 5. The analyzer 
automatically calculates the analyte concentration of each sample in pmol/l or pg/mL.  
 
Folate 
Folate was measured on the Cobas 8000 system from Roche/Hitachi with ECLIA 11 using the 
competitive principle. The method has been standardized against World Health Organization 
International Standard NIBSC-code:03/178, where earlier generations are traceable to “Bio-Rad 





Glucose was measured on the Cobas 8000 system from Roche/Hitachi using an in vitro test for the 
quantitative determination of glucose in human serum. The test principle is an ultraviolet test with 
enzymatic references method with hexokinase 12. Glucose values for human serum obtained on the 
Roche/Hitachi c 701 analyzer (y) were compared with those determined using the same reagent on 
the Roche/Hitachi cobas 501 analyzer (x). This method has been standardized against isotope 
dilution mass spectrometry reference measurement procedure 5. The analyzer automatically 
calculates the analyte concentration of each sample by conversion factor mg/dl x 0.0555= mmol/l.  
High-Sensitivity C-Reactive Protein 
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High-Sensitivity C-Reactive Protein was measured on the Cobas 8000 system from Roche/Hitachi with 
an immunoturibidimetric assay 13,14. The method has been standardized against the reference 
preparation of the IRMM BCR470/CRM470 (RPPHS)5,15,16. The analyzer automatically calculates the 
analyte concentration of each sample by conversion factor mg/Ll x 9.52= nmol/L.  
 
Apolipoprotein A  
Apolipoprotein A was measured on the Cobas 8000 system from Roche/Hitachi with an 
immunoturibidimetric assay 17,18. The method has been standardized against the IFCC SP1-01 
reference standard ( WHO-IRP October 1992) 5. The analyzer automatically calculates the analyte 
concentration of each sample in by conversion factor mg/dL x 0.01= g/L.  
 
Apolipoprotein B  
Apolipoprotein B was measured on the Cobas 8000 system from Roche/Hitachi with  a 
immunoturibidimetric assay 17,18. The method has been standardized against the IFCC SP3-07 
reference standard ( World Health Organization-IRP October 1992) 5. The analyzer automatically 
calculates the analyte concentration of each sample by conversion factor mg/dL x 0.01= g/L .  
 
Cholesterol 
Cholesterol was measured on the Cobas 8000 system from Roche/Hitachi with a homogeneous 
enzymatic colorimetric method 19,20. The method has been standardized against the designated 
Centers for Disease Control reference method (designated comparison method). The standardization 
meets the requirements of the “HDL Cholesterol Method Evaluation Protocol for Manufactures” of 
the US national Reference System of Cholesterol, (Cholesterol Reference Method Laboratory 
Network, CRMLN), November 1994 5. The analyzer automatically calculates the analyte concentration 
of each sample by conversion factor mg/dL x 0.0259=mmol/L.  
 
Low-density lipoprotein Cholesterol 
Low-density lipoprotein (LDL) Cholesterol was measured on the Cobas 8000 system from 
Roche/Hitachi with a homogeneous enzymatic colorimetric method 20-22. The method has been 
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standardized against the beta quantification method as defined in the recommendations in the LDL 
Cholesterol Certification Protocol for Manufacturers 5. The analyzer automatically calculates the 
analyte concentration of each sample by conversion factor mg/dL x 0.0259= mmol/L.  
High-density lipoprotein Cholesterol 
High-density lipoprotein (HDL) Cholesterol was measured on the Cobas 8000 system from 
Roche/Hitachi with a homogeneous enzymatic colorimetric method. The method has been 
standardized against the designated CDC reference method (designated comparison method) 23. The 
standardization meets the requirements of the “HDL Cholesterol Method Evaluation Protocol for 
Manufacturers” of the US National Reference System of Cholesterol, Cholesterol Reference Method 
Laboratory Network (CRMLN), November 1994 5. The analyzer automatically calculates the analyte 
concentration of each sample by conversion factor mg/dL x 0.0259=mmol/L.  
Triglycerides 
Triglycerides were measured on the Cobas 8000 system from Roche/Hitachi with a homogeneous 
enzymatic colorimetric method. The method has been standardized against the designated ID/MS 
method 5,14,24. The analyzer automatically calculates the analyte concentration of each sample by 
conversion factor mg/dL x 0.0113=mmol/L.  
25-hydroxy-vitamin D 
25-hydroxy-vitamin D [25(OH)D] was measured by the IDS-iSYS 25-Hydroxy Vitamin Dˢ assay on the 
IDS-iSYS analyzer (IDS Ltd., Boldon, UK). 25(OH)D analysis in serum blood samples was performed at 
the Department of Food and Environmental Sciences, University of Helsinki. The laboratory method 
is standardized, validated and certified by “The vitamin D Standardization Program” 
(VDSP)  https://ods.od.nih.gov/Research/vdsp.aspx. 
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